Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Paroxetine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | GRK2 | P25098 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | MPO | P05164 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Paroxetine SCHEMBL29358021 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL2583823 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL114238 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL10643985 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL8732632 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL15855060 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL1560678 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL27799 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL1945816 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 | |
| Paroxetine SCHEMBL10643980 | 1.00 | CYP3A4 (1.00) | CYP3A4GRK2SLC6A4TP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | AGENEBIO, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20230301922-A1 | Layered Pharmaceutical Formulations | NALPROPION PHARMACEUTICALS LLC (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230098667-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. | 2023-03-30 | — | — | US | disclosed |
| US-20210009602-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | HAGER BIOSCIENCES | 2021-01-14 | — | — | US | disclosed |
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | AGENEBIO, INC. (US) | 2017-09-07 | — | — | US | disclosed |
| WO-2017066434-A1 | BRAIN-DERIVED NEUROTROPHIC FACTOR (BDNF)-TROPOMYOSINE KINASE B (TRKB) INHIBITION FOR IMPROVING COGNITIVE DEFICITS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2017-04-20 | — | — | WO | disclosed |
| US-20160338965-A1 | LAYERED PHARMACEUTICAL FORMULATIONS | WILMINGTON SAVINGS FUND SOCIETY, FSB | 2016-11-24 | — | — | US | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20150164806-A1 | LAYERED PHARMACEUTICAL FORMULATIONS | VALORBEC SOCIETE EN COMMANDITE (CA) | 2015-06-18 | — | — | US | disclosed |
| US-20130177602-A1 | LAYERED PHARMACEUTICAL FORMULATIONS | OREXIGEN THERAPEUTICS, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2005079756-A2 | COMBINATION OF A NMDA RECEPTOR ANTAGONIST AND AN ANTI-DEPRESSIVE DRUG MAO-INHIBITOR OR A GADPH-INHIBITOR FOR THE TREATMENT OF PSYCHIATRIC CONDITIONS | NEUROMOLECULAR, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
| US-20050181070-A1 | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss | U.S. BANK NATIONAL ASSOCIATION, AS COLLATERAL AGENT | 2005-08-18 | — | — | US | disclosed |
| EP-1553955-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | Combinatorx, Incorporated (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| WO-2005037203-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF IMMUNOINFLAMMATORY DISORDERS | COMBINATORX, INCORPORATED (US) | 2005-04-28 | — | — | WO | disclosed |
| EP-1180021-A4 | REGIMEN AND KIT FOR AMELIORATION OF PREMATURE EJACULATION | PENTECH PHARMACEUTICALS INC (US) | 2005-01-19 | — | — | EP | disclosed |
| WO-2004030618-A2 | METHODS AND REAGENTS FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH INCREASED LEVELS OF PROINFLAMMATORY CYTOKINES | COMBINATORX, INCORPORATED (US) | 2004-04-15 | — | — | WO | disclosed |
| EP-1180021-A1 | REGIMEN AND KIT FOR AMELIORATION OF PREMATURE EJACULATION | Pentech Pharmaceuticals, Inc. (US) | 2002-02-20 | — | — | EP | disclosed |
| WO-2000067729-A1 | REGIMEN AND KIT FOR AMELIORATION OF PREMATURE EJACULATION | PENTECH PHARMACEUTICALS, INC. (US) | 2000-11-16 | — | — | WO | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050181070-A1 | Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss | GAP43, PYGB, GPR119 | SLC6A4 201/4885CYP3A4 2124/4885GRK2 358/4885 |
| US-20210009602-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | SLC6A4 1403/4885CYP3A4 2409/4885GRK2 118/4885 |
| US-12024525-B2 | Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment | GRM5, GABRA5, GABRE | SLC6A4 1413/4885CYP3A4 2337/4885GRK2 114/4885 |
| US-20230098667-A1 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GABRA5, GRM5, GABRA1 | SLC6A4 1442/4885CYP3A4 2333/4885GRK2 89/4885 |
| US-20170253603-A2 | BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT | GRM5, GABRA5, GABRE | SLC6A4 1403/4885CYP3A4 2409/4885GRK2 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.